Lupin Launches Clobazam Oral Suspension

Pharma major Lupin announced the launch of Clobazam Oral Suspension, 2.5mg/mL, having received an approval from the United States Food and Drug Administration (FDA) earlier. Lupin’s Clobazam Oral Suspension, 2.5mg/mL is the generic version of Lundbeck Pharmaceuticals LLC’s Onfi Oral Suspension, 2.5mg/mL. It is indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older. Clobazam Oral Suspension, 2.5mg/mL had annual sales of USD 253 million in the US (IQVIA MAT December 2018). – Medical Buyer Bureau